Commentaries
Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis

https://doi.org/10.1016/j.diabet.2015.12.005Get rights and content

Section snippets

Disclosure of interest

No sources of funding were used to assist in the preparation of this manuscript. The authors declare that they have no competing interest.

A.J. Scheen has received lecture/advisor fees from AstraZeneca/BMS, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi and Takeda.

References (46)

  • A. Ceriello et al.

    Understanding EMPA-REG OUTCOME

    Lancet Diabetes Endocrinol

    (2015)
  • L. Ryden et al.

    ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)

    Eur Heart J

    (2013)
  • P. Gaede et al.

    Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

    N Engl J Med

    (2003)
  • P. Gaede et al.

    Effect of a multifactorial intervention on mortality in type 2 diabetes

    N Engl J Med

    (2008)
  • A.J. Scheen

    Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor

    Clin Pharmacokinet

    (2014)
  • B. Zinman et al.

    Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes

    N Engl J Med

    (2015)
  • S.E. Inzucchi et al.

    SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials

    Diab Vasc Dis Res

    (2015)
  • A.J. Scheen

    Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus

    Drugs

    (2015)
  • H.J. Lambers Heerspink et al.

    Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

    Diabetes Obes Metab

    (2013)
  • Group UKPDS

    Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

    Lancet

    (1998)
  • Group UKPDS

    Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

    Lancet

    (1998)
  • B.M. Scirica et al.

    Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

    N Engl J Med

    (2013)
  • W.B. White et al.

    Alogliptin after acute coronary syndrome in patients with type 2 diabetes

    N Engl J Med

    (2013)
  • Cited by (55)

    • Possible mechanisms of cardiovascular benefits of SGLT2 inhibitors

      2019, Archives of Cardiovascular Diseases Supplements
    • Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes

      2019, Diabetes and Metabolism
      Citation Excerpt :

      SGLT2is exert their glucose-lowering effects by promoting glucosuria, an effect that also results in body-weight and fat-mass reductions. In addition to these effects, they increase natriuresis and osmotic diuresis, thereby lowering arterial blood pressure and plasma overload [107], all factors that may contribute to better CV and renal outcomes and rates of mortality [108]. In addition, switching from low-dose thiazide diuretics to SGLT2is has improved various metabolic parameters (HbA1c, fasting plasma glucose, serum uric acid, BMI, visceral fat area) without affecting blood pressure in patients with T2DM and hypertension [109].

    View all citing articles on Scopus
    View full text